GlassScriptPhysician profile
Choisette Damus
NPI 1639544018
$2,402.15
in general payments reported to CMS, 2019-2025
11 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $616 · 2022: $501 · 2023: $556 · 2024: $499 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $444.15 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Viiv Healthcare Company | $435.16 | 2021-2024 | Apretude |
| Teva Pharmaceuticals USA, INC. | $337.25 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $122.32 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $122.10 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $121.00 | 2023 | Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $112.71 | 2022 | |
| Gilead Sciences, INC. | $112.64 | 2021 | |
| Abbvie INC. | $89.46 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.70 | 2024 | Hetlioz, Fanapt |
| Merck Sharp & Dohme LLC | $17.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Choisette Damus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.